Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation
Open Access
- 17 July 2026
- journal article
- review article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (10) , 669-677
Abstract
Artificial intelligence (AI) has emerged as a promising adjunct in surgical pathology, particularly in the diagnosis of prostate cancer, where variability in interpretation or missed cancer foci can significantly affect patient management. This review provides a concise, practice-oriented overview of the two Food and Drug Administration (FDA)-cleared AI tools for prostate biopsy interpretation: Paige Prostate Detect and Ibex Prostate Detect (formerly Galen Second Read). We examine their regulatory indications, diagnostic performance and integration requirements within digital pathology workflows. Emphasis is placed on real-world implementation considerations, including variation in technical inputs and the level at which data are analysed. We highlight less obvious risks, such as domain shift and the potential for inequitable performance in under-represented patient populations. Trade-offs between sensitivity and specificity, particularly in the context of AI-assisted pathologist assessments, are discussed using data from clinical validation studies. We also consider the variable impact of AI tools depending on the user’s expertise, noting enhanced diagnostic consistency for general pathologists. By highlighting both the opportunities and limitations of integrating AI into routine practice, we aim to provide pathologists with a pragmatic understanding of how these systems may influence diagnostic workflows and to emphasise that FDA clearance must be complemented by local validation as well as ongoing performance monitoring to ensure safe and equitable deployment.Keywords
This publication has 39 references indexed in Scilit:
- An artificial intelligence solution for evaluation of prostate needle core biopsy specimens: impact in a non-specialist settingVirchows Archiv, 2026
- Validation, implementation, and impact of an AI model in routine practice for pathologic diagnosis of prostate cancer in an academic medical centerJournal of Pathology Informatics, 2026
- Digital pathology platforms with integrated AI algorithms: a structured landscape analysis and recommendations for clinical implementationVirchows Archiv, 2026
- Prostate CancerJAMA, 2025
- Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosis—real-world experienceJournal of Pathology Informatics, 2024
- Can incorrect artificial intelligence (AI) results impact radiologists, and if so, what can we do about it? A multi-reader pilot study of lung cancer detection with chest radiographyEuropean Radiology, 2023
- Artificial intelligence–assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsiesVirchows Archiv, 2023
- Independent real‐world application of a clinical‐grade automated prostate cancer detection systemThe Journal of Pathology, 2021
- Lessons Learned About Autonomous AI: Finding a Safe, Efficacious, and Ethical Path Through the Development ProcessAmerican Journal of Ophthalmology, 2020
- Evidence Supports a Faster Growth Rate and/or Earlier Transformation to Clinically Significant Prostate Cancer in Black Than in White American Men, and Influences Racial Progression and Mortality DisparityJournal of Urology, 2010